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Abstract MicroRNAs (miRNAs) can be found in a wide range of tissues and body fluids, and their
specific signatures can be used to determine diseases or predict clinical courses. The miRNA profiles
in biological samples (tissue, serum, peripheral blood mononuclear cells or other body fluids) differ
significantly even in the same patient and therefore have their own specificity for the presented con-
dition. Complex profiles of deregulated miRNAs are of high interest, whereas the importance of
non-expressed miRNAs was ignored. Since miRNAs regulate gene expression rather negatively,
absent miRNAs could indicate genes with unaltered expression that therefore are normally
expressed in specific compartments or under specific disease situations. For the first time,
non-detectable miRNAs in different tissues and body fluids from patients with different diseases
(cardiomyopathies, Alzheimer’s disease, bladder cancer, and ocular cancer) were analyzed and com-
pared in this study. miRNA expression data were generated by microarray or TaqMan PCR-based
platforms. Lists of absent miRNAs of primarily cardiac patients (myocardium, blood cells, and
serum) were clustered and analyzed for potentially involved pathways using two prediction
platforms, i.e., miRNA enrichment analysis and annotation tool (miEAA) and DIANA miRPath.
Extensive search in biomedical publication databases for the relevance of non-expressed miRNAs in
predicted pathways revealed no evidence for their involvement in heart-related pathways as
indicated by software tools, confirming proposed approach.
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Introduction
Cardiovascular diseases as life-threatening diseases are the
most common cause of death in Western European countries
[1]. Myocarditis and non-ischemic dilated cardiomyopathy
(DCM) are acute or chronic disorders of heart muscle which
arises mainly from myocardial inflammation or infections by
cardiotropic viruses [1–6]. More than 12 million patients in
Europe and 15 million patients in the United States (US) are
suffering from heart failure including four million with
DCM, according to an estimation of the European Society
of Cardiology (ESC) [3]. The traditional clinical diagnosis
based on individual patient’s clinical symptoms, medical and
family history, laboratory and imaging evaluations should be
expanded by endomyocardial biopsy (EMB) diagnostics (virol-
ogy, histology, and immunohistochemistry) to confirm
myocardial disease for following treatment decisions [3,7,8].
Improvements in human genetic studies and the
continuously-expanding field of biomarker discovery revealed
the potential of physiological biomarkers such as microRNAs
(miRNAs) or gene expression profiles for diagnosis of complex
diseases such as cardiomyopathies and for applications in per-
sonalized medicine [9–14]. miRNA profiling can serve as a new
exciting tool in modern diagnostics, which is comparable to
gene expression analysis but with less amount of analytes. In
addition, approximately 2500 human mature miRNAs have
been discovered so far, which seems to be relatively small in
number compared to the enormous number of genes discov-
ered [15–21].
miRNAs are 20–22 nucleotides in length and highly-
conserved non-coding RNAs. They have been demonstrated
to play multiple roles in negative or positive regulation of gene
expression including transcript degradation, translational sup-
pression, or transcriptional and translational activation. miR-
NAs are present in a wide range of tissues [10,15,18–20,22–26].
In body fluids such as serum, plasma or spinal fluid, miRNAs
are protected from endogenous RNase activity by inclusion in
exosomes or protein complexes [19,22,24,25]. Due to their high
biostability, circulating miRNAs can be used as reliable
blood-based markers to identify cardiovascular or other
human disorders [11,13,14,16–19].
Up to now, about 800 expressed miRNAs have been exper-
imentally detected in EMBs [21]. As shown for DCM, hyper-
trophic and inflammatory cardiomyopathy, the expression of
miRNAs is characteristically altered in heart tissue [17]. Differ-
ential miRNA patterns allow the identification of different
heart disorders or disease situations [17,21]. The role of these
human miRNAs in pathogenesis [18] highlights their value as
potential molecular biomarkers for complex diseases such as
cardiomyopathies [16,27,28]. The discriminating power of sin-
gle miRNAs for diagnosis of complex diseases can be increased
by its integration in a larger panel presenting a specific miRNA
signature. The application of myocardial miRNA profiling
allows the differentiation of distinct phases of viral infections
and the prediction of the clinical course of virally-induced dis-
ease at the time point of primary diagnostic biopsy
[16,11,28,12]. In the same individual, miRNA signatures in tis-
sue, serum, peripheral blood mononuclear cells (PBMCs), or
other body fluids show specific features for the current condi-
tion. Therefore these disease-specific biomarkers are of
increasing interest for personalized medicine [12,29,30].
Non-expressed miRNAs in their entirety were ignored and cor-
responding data were rarely presented [25]. Due to rather neg-
ative regulation of miRNAs in general, absent miRNAs would
indicate genes which are not altered in terms of expression and
therefore normally expressed in specific compartments. Occur-
rence of previously absent miRNAs could be an easy predictor
for changes in functional activity in analyzed biological sample
or in the disease situation under examination.
Analyses of expression data by bioinformatic software
(miEAA and DIANA [31]) are currently based on two strate-
gies: (1) presentation of published data of deregulated miR-
NAs and their association with affected pathways or diseases
and (2) prediction of involved miRNAs extrapolated from
data of differentially expressed genes in corresponding disease
situation as presented in the Kyoto Encyclopedia of Genes and
Genomes (KEGG) schemata. Comprehensive expression data
of indicated pathways or associated disorders are limited by
availability of larger patient cohorts and comparability of ana-
lytical methods.
In this article, we focused on the non-detectable miRNAs
measured on different platforms in myocardial tissue, blood
cells, and serum in a large cohort of cardiac patients suffering
from different forms of inflammatory or virally-induced heart
muscle diseases [1–5]. The underlying disease was diagnosed by
routine EMB [3,6,32,33]. The bioinformatic analyses of gener-
ated data using two current freely-available prediction tools
revealed no evidence for their involvement in heart-related
pathways. Experimental findings for cardiac patients were con-
firmed by comparisons of absent miRNAs in large cohorts of
patients with different diseases [22,24,25] measured on the
same analytical platforms.
Results
We performed miRNA expression studies with three analytical
platforms, the Geniom Biochips (Febit, Heidelberg, Germany)
and two TaqMan PCR-based high-throughput systems includ-
ing low density array (LDA) and OpenArray (Thermo Fisher
Scientific, Waltham, MA, USA). Based on the analysis of
deregulated miRNAs, we presented lists and pathways of
non-detectable miRNAs in different tissues of primarily car-
diac patients. All data were generated in the same laboratory
to facilitate comparative data analysis.
Comparison of absent miRNAs in EMBs, serum, and PBMCs of
cardiac patients
miRNA preparations were obtained for patients with inflam-
matory or virally-induced cardiomyopathies from EMBs
(n= 284), PBMCs (n= 67), or serum (n= 287) including
corresponding controls (Table 1). miRNAs in EMBs and
serum were measured using two different platforms, which
cover different sets of miRNAs (Table 2). Therefore, an addi-
tive list for EMBs and serum of absent miRNAs of each sys-
tem was generated and used for all following calculations. A
list of absent miRNAs was generated to indicate common or
unique tissues in which miRNAs are not detectable
(Table S1). Furthermore, a Venn diagram analysis was per-
formed to reveal overlapping absent miRNAs in EMBs,
serum, and PBMCs and miRNAs exclusively absent in partic-
ular tissues. As shown in Figure 1, we detected 1107 miRNAs
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in total absent in 1–3 sample groups. 179 miRNAs were found
to be absent in all three sample sources from cardiac patients.
The miRNA Enrichment Analysis and Annotation Tool
(miEAA) analysis showed that these miRNAs are involved
in 685 pathways, implying possibly unaltered genes in these
pathways. 7 out of 685 (1.0 %) pathways were indicated to
be heart-related. In addition, there are 2 (0.3 %) pathways
described for viral myocarditis and DCM. Six miRNAs seem
to be associated with these 2 pathways, which include hsa-
miR-19b-1-5p, hsa-miR-1295a, hsa-let-7a-5p, hsa-miR-99b-
3p, hsa-miR-16-1-3p, and hsa-miR-34b-3p.
On the other hand, some miRNAs are absent only in one
sample group. These include 3 miRNAs exclusively absent in
EMBs, 6 absent in PBMCs, and 650 absent in serum. For
miRNAs absent in EMB or PBMC samples, miEAA
revealed 8 pathways but none were heart-related pathways,
whereas DIANA miRPath prediction indicated 3 heart-
related KEGG pathways for EMBs (57 others) and one for
PBMCs (50 others), respectively. For the 650 miRNAs exclu-
sively absent in serum samples, miEAA analysis revealed 14
pathways other than heart-relates ones. Since these patients
suffer from cardiac diseases, the missing heart-related path-
ways are in concordance with the absence of these 650 miR-
NAs in serum. DIANA miRPath analysis for these miRNAs
could not be performed due to limited miRNA input
possibility.
Comparison of absent miRNAs in cardiac patients to those in
patients with other diseases
To validate experimental findings for cardiac patients and min-
imize methodological bias, panels of absent RNAs were evalu-
ated with data from large cohorts of patients with different
diseases [22,24,25] measured on the same analytical platforms.
We compared the aforementioned 1107 miRNAs absent in
any one or more sample groups of EMBs, serum, and PBMCs
taken from cardiac patients to those absent in spinal fluid (Alz-
heimer’s disease patients), urine (bladder cancer patients) or
ocular fluid (ocular cancer patients) samples. There are totally
432, 217, and 187 miRNAs absent in spinal fluid, ocular fluid,
and urine samples, respectively. Venn diagram showed that 24
absent miRNAs were found to be common among all different
tissue types tested. These 24 absent miRNAs were listed in
Table 3 [34–49]. On the other hand, some miRNAs are only
absent in one particular group. We found 13, 9, and 31 miR-
NAs specifically absent in spinal fluid, urine and ocular fluid
samples, respectively (Figure 2).
Pathway comparison using different prediction tools
Next, different pathway prediction tools were employed to
analyze the pathways involving the 24 absent miRNAs shared
Table 1 Number of analyzed samples sorted by diagnosis and sample type of cardiac patients
Diagnosis EMB PBMC Serum
Virally-induced myocarditis total 192 17 166
Adenovirus (ADV) 8 16
Enterovirus (coxsackievirus) 66 72
Human herpes virus 6 (HHV6) 5 12
Chromosomal integrated HHV6 (ciHHV6) 12 13
Parvovirus B19 118 53
Active myocarditis (MCA) 3 8 18
Dilated cardiomyopathy (DCM) 8 6 19
DCM with inflammation (DCMi) 5 7 11
Idiopathic giant cell myocarditis (IGCM) 12 2 8
Amyloidosis 13 4 12
Cardiac sarcoidosis (CS) 6 8
Clinical myocarditis without inflammation (MCno) 4 11 6
Borderline myocarditis (MC-BL) 12 8
Virus-free without inflammation (Vneg) 41 6
Healthy blood donor 25
In total 284 67 287
Note: EMB, endomyocardial biopsy; PBMC, peripheral blood mononuclear cell.
Table 2 Number of analyzed samples sorted by platform and sample type
Sample tissue
Analyzed samples per miRNA analysis platform
Febit Geniom Biochip
(906 miRNAs)
TaqMan OpenArray
(756–1204 miRNAs)
TaqMan low density array
(756 miRNAs)
EMB 79 137 68
PBMC 67 – –
Serum 50 237 –
Spinal fluid – 50 –
Urine – – 12
Ocular fluid – – 5
Note: EMB, endomyocardial biopsy; PBMC, peripheral blood mononuclear cell.
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by all samples examined (Table 3). miEAA analysis revealed
that these 24 absent miRNAs were involved in only one path-
way and in regulation of 10 genes (Table 4) and one disease
related to the analyzed miRNAs (Table 5), whereas more than
80 KEGG pathways were predicted with DIANA tool Tar-
Base (Table 6) or microT (Table 7). As shown in Tables 4–7,
the number of predicted pathways varied greatly depending
on selected prediction algorithm. In addition, the predicted
pathways based on the same 24 miRNAs showed associations
with completely different diseases or organs using the two soft-
ware tools. These data raise the question about plausibility and
authenticity of the used pathway analysis tools.
Discussion
The importance of differentially-expressed miRNAs for char-
acterization of various disease situations has been shown
impressively [19,22–25,28,30]. miRNAs are mainly negative
regulators of gene expression. Therefore absent miRNAs could
indicate genes which are not affected for the disease situation
examined or in the corresponding sample material. The differ-
ent pattern of non-expressed miRNAs in separate tissues or
organs could be explained by their biological functions.
The current study described, for the first time, the set of
non-expressed miRNAs of the largest published cohort of
patients (more than 200, including controls) with inflammatory
or virally-induced cardiomyopathies that were diagnosed using
EMBs [3,4,6,32]. Absent miRNAs were revealed with different
analytical platforms and compared to data from other diseased
patients (Alzheimer’s disease, ocular cancer, bladder cancer)
measured with identical assays in the same laboratory. The
demonstration of differentially regulated miRNAs was not
the aim of this study, corresponding data for the
differentially-regulated miRNAs were shown previously
[16,22,24,25,28].
Bioinformatic evaluation of identified absent miRNAs was
performed by application of two freely-available pathway
Table 3 miRNAs not expressed in any sample type examined in the current study
miRNA Functional roles Refs.
hsa-miR-105-5p NA
hsa-miR-129-5p Hepatitis C and hepatocellular carcinoma [34,35]
hsa-miR-33b-5p NA
hsa-miR-127-5p NA
hsa-miR-154-5p NA
hsa-miR-199b-5p Prostate cancer [36]
hsa-miR-216a-5p NA
hsa-miR-216b-5p NA
hsa-miR-217 Tumor suppressor for various tumors [37–39]
hsa-miR-299-3p Senescence of endothelial cells [40]
hsa-miR-330-5p NA
hsa-miR-369-3p Crohn’s disease [41]
hsa-miR-380-3p NA
hsa-miR-98-5p Hepatitis B [42]
hsa-miR-122-5p Hepatitis B [42,43]
hsa-miR-147b NA
hsa-miR-188-3p Dendritic plasticity and synaptic transmission [44]
hsa-miR-18b-5p Epstein-Barr virus infection [45]
hsa-miR-198 Retinoblastoma [46]
hsa-miR-208b-3p NA
hsa-miR-339-5p Lung cancer and oocytogenesis [47,48]
hsa-miR-370-3p NA
hsa-miR-371a-3p NA
hsa-miR-377-3p Anxiety-related traits [49]
Note: NA means no literature proof found for any disease association with the specified miRNA.
EMB Serum
PBMC
Figure 1 Venn diagram of absent miRNAs in different sample
types from cardiac patients
Venn diagram analysis was performed for absent miRNAs that
are specific to each sample type and overlapping between different
sample types such as EMBs (total 296 absent miRNAs), serum
(total 1092 absent miRNAs), and PBMCs (total 346 absent
miRNAs) of cardiac patients. EMB, endomyocardial biopsy;
PBMC, peripheral blood mononuclear cell.
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Figure 2 Venn diagram of absent miRNAs in EMBs, PBMCs, and other body ﬂuids
Venn diagram analysis was performed for absent miRNAs that are specific to each sample type and overlapping between different sample
types. These include EMB, serum, PBMC samples from cardiac patients (total 1107 absent miRNAs), spinal fluid samples from
Alzheimer’s disease patients (total 432 absent miRNAs), ocular fluid from ocular cancer patients (total 217 absent miRNAs), and urine
from bladder cancer patients (total 187 absent miRNAs). A complete list of the 24 absent miRNAs in all sample types examined and their
related pathways are shown in Tables 3–7.
Table 4 Overrepresented pathways and genes generated for the 24 commonly-absent miRNAs using miEAA ORA with FDR adjustment
Category Name of pathway/gene P value Expected No. of miRNAs involved
Target pathway Chromosomal location (Chromosome 14) 0.0002342 0.144668 8
Target gene A2M 0.0351652 0.10582 2
Target gene CHST3 0.0351652 0.0705467 2
Target gene FUNDC2 0.0351652 0.141093 2
Target gene MOB3B 0.0351652 0.141093 2
Target gene SLC19A2 0.0382447 0.176367 2
Target gene SMAD7 0.0351652 0.388007 3
Target gene TMEM8A 0.0382447 0.176367 2
Target gene TRAM2 0.0351652 0.141093 2
Target gene TRIB1 0.0382447 0.176367 2
Note: Overrepresented pathways were predicted using miRBase, while target genes regulated by miRNAs were predicted using miRTarBase.
miEAA, microRNA enrichment analysis and annotation; ORA, over-representation analysis; FDR, false discovery rate; A2M, alpha-2-
macroglobulin; CHST3, carbohydrate sulfotransferase 3; FUNDC2, FUN14 domain containing 2; MOB3B, MOB kinase activator 3B; SLC19A2,
solute carrier family 19 member 2; SMAD7, SMAD family member 7; TMEM8A, transmembrane protein 8A; TRAM2, translocation associated
membrane protein 2; TRIB1, tribbles pseudokinase 1.
Table 5 Predicted diseases by enriched pathways generated for the 24 commonly-absent miRNAs using miEAA G(SEA) with FDR
adjustment
Category Predicted disease Enrichment P value No. of miRNAs involved
Diseases Acute myocardial infarction deregulated Enriched 0.0411899 10
Note: Disease data were based on published studies about miRNA profiles in peripheral blood.
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prediction tools (miEAA and DIANA miRPath) to confirm
experimental findings. For cardiac patients, 6 heart-related
pathways were recovered using miEAA. For the 6 miRNAs
commonly not expressed in EMBs, serum, and PBMCs of
cardiac patients, the software predicted association with
myocarditis and DCM. Intensive search of biomedical publica-
tion databases provided no hint for their involvement in heart
muscle diseases. Instead, hsa-miR-16-1-3p is related to chronic
lymphocytic leukemia [50] and age-related cataract [51],
whereas hsa-miR-34b-3p is related to spermatogenesis [52].
Similarly, hsa-let-7a-5p seems to be related to infectious
mononucleosis but not cardiac diseases [45]. Moreover, there
lacks proof in literature or through in silico prediction tools
for the involvement of the remaining 3 miRNAs in any disease
or pathway.
DIANA analysis revealed one DCM-related pathway based
on the 24 common miRNAs that are never detected in any of
EMB, serum, PBMC, spinal fluid, ocular fluid or urine sam-
ples. Literature screening in PubMed retrieved no publications
related to DCM or other cardiomyopathies for all 24 common
absent miRNAs, therefore no experimental proof as well
(Tables 3–7).
Both examples of detailed search (6 miRNAs and 24
miRNAs) for the relevance of miRNAs in distinct pathways
revealed no evidence for their involvement in heart-related
pathways as stated in DIANA tool. Pathway prediction tools
could generate a broad amount and variety of potential net-
works which might only exist in theory but not in reality.
In addition, these prediction tools have their limits in terms
of amount of miRNAs that can be uploaded for analysis
(especially DIANA tool), literature evidence of theirs pre-
dicted pathways, and comparability between different predic-
tion tools. The best way to overcome this deficiency in
pathway prediction is the evaluation of larger sample cohorts
or multiple data sources. The involvement of sets of non-
expressed miRNAs for more diseases, as presented in this
study, will sharpen the predictive power of bioinformatic
analyses. These data are easily available but often not
requested for publication. In future, predicted pathways
should be double checked against list of absent miRNAs.
The theoretical output of prediction tools shows high diver-
gence from experimental validation, at least for our study.
Therefore, users of prediction tools should take caution and
assess the output critically.
The spectrum of non-expressed miRNAs in body fluids for
defined diseases such as serum of patients suffering from car-
diomyopathies is of keen interest. Today circulating miRNAs
have the most important scientific and diagnostic impact
[19,22,25,26,29,30]. In this article, we described for the first
time a panel of absent miRNAs in serum, PBMCs, EMBs,
spinal fluid, urine, and ocular fluid of diseased patients includ-
ing corresponding healthy controls. Implementing this spec-
trum in comparison to miRNA studies in different disorders,
disease-specific miRNAs can be identified expeditiously.
Further studies have to confirm especially which of these
absent serum miRNAs in cardiomyopathies are not versatile.
Circulating miRNAs will be the novel diagnostic biomarkers,
also for heart muscle diseases [14,15,21,24,26]. Some of these
serum miRNAs are present in other disorders not correspond-
ing to cardiomyopathies, which could be of scientific interest
for understanding of specific pathomechanisms or finally as
therapeutic targets for miRNA modulation to deal with dis-
crete disease situations.
There are some limitations in the current study. Three ana-
lytical platforms were used in generating data for overlapping
sample sets to infer miRNAs absent alone or in different com-
binations. EMBs and PBMCs were measured with microarray-
based technology for former sets of available miRNAs
(miRBase v14), whereas Taqman PCR-based analysis were
performed later and used to measure miRNAs in serum
(OpenArrays, miRBase v16 and higher), EMBs (LDA and
OpenArrays) [15], spinal fluid (OpenArray), urine (LDA),
and ocular fluid (LDA). In addition, only two freely-
available software tools were used for pathway prediction.
The bioinformatic and translational perspective of pre-
sented approach is manifold. This first preliminary study on
non-detectable miRNAs should sensitize scientific community
to present not only data of deregulated candidates, but also
data of completely absent miRNAs [25] as a valuable dataset
for improvement of commonly used software tools. Non-
detectable miRNAs should be excluded from further predic-
tion of corresponding pathways. Otherwise the collection of
these data for all tissues, cells, or body fluids would be an
important reservoir for future research or also pharmaceutical
studies, and thus should be propagated by bioinformatics. The
unexpected finding of previously-described non-expressed
miRNAs in an experiment or clinical study will facilitate the
identification of newly involved pathways or functional dys-
regulations in an observed setup.
Material and methods
Samples
EMB, PBMC, and serum samples were obtained from healthy
controls and patients suffering from inflammatory or virally
induced myocarditis as shown in Table 1 [9,10,15,16,11,
53,54]. The study was performed within the Transregional Col-
laborative Research Centre (Inflammatory Cardiomyopathy–
Molecular Pathogenesis and Therapy) [Sfb/Tr19]. The study
protocol was approved by the local ethics committees of the
participating clinical centers, as well as by the committees of
the respective federal states. An informed written consent
was obtained from each participant.
Spinal fluid samples were received from healthy controls and
patients suffering from Alzheimer’s disease, with the ethical
statement described previously [25]. Urine samples were
acquired from healthy controls and patients harboring bladder
cancer, with the ethical statement described previously [22,24].
In addition, we analyzed pooled ocular fluid from random
patients.
miRNA isolation
miRNAswere obtained frompatients, usingmirVanaTMmiRNA
Isolation Kit (Thermo Fisher Scientific, Waltham, MA, USA)
resp. mirVanaTM PARISTMRNA andNative Protein Purification
Kit (Thermo Fisher Scientific, Waltham, MA, USA) for low
content samples such as serum, urine, ocular fluid, and spinal
fluid according to manufacturer’s instructions. All presented
expression studies were performed in the same laboratory.
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Table 6 Pathways generated for the 24 commonly-absent miRNAs using DIANA TarBase
KEGG pathway name KEGG pathway ID P value No. of genes No. of miRNAs
01 TGF-beta signaling pathway hsa04350 2.09E-25 44 15
02 ErbB signaling pathway hsa04012 1.05E-26 46 14
03 Chronic myeloid leukemia hsa05220 1.11E-25 41 14
04 Ubiquitin mediated proteolysis hsa04120 6.51E-15 59 16
05 Prostate cancer hsa05215 9.71E-15 39 15
06 Focal adhesion hsa04510 3.25E-13 77 16
07 Wnt signaling pathway hsa04310 7.25E-13 65 15
08 Long-term potentiation hsa04720 7.77E-13 32 11
09 Glioma hsa05214 8.35E-13 35 14
10 Dopaminergic synapse hsa04728 1.65E-12 54 15
11 Non-small cell lung cancer hsa05223 1.99E-12 27 13
12 Pancreatic cancer hsa05212 4.78E-12 34 14
13 Melanoma hsa05218 4.78E-12 32 14
14 Acute myeloid leukemia hsa05221 3.55E-11 26 15
15 Pathways in cancer hsa05200 6.73E-12 121 17
16 PI3K-Akt signaling pathway hsa04151 9.69E-11 114 17
17 Axon guidance hsa04360 2.76E-10 56 14
18 Renal cell carcinoma hsa05211 1.03E-09 33 17
19 Prion diseases hsa05020 8.13E-09 12 12
20 mTOR signaling pathway hsa04150 1.19E-08 28 12
21 Insulin signaling pathway hsa04910 1.86E-08 51 16
22 Dorsoventral axis formation hsa04320 1.89E-08 14 12
23 Bladder cancer hsa05219 3.31E-08 20 10
24 GnRH signaling pathway hsa04912 3.61E-08 36 16
25 Hepatitis B hsa05161 4.18E-09 57 16
26 T cell receptor signaling pathway hsa04660 5.77E-09 41 15
27 Regulation of actin cytoskeleton hsa04810 8.72E-08 77 16
28 Fc gamma R-mediated phagocytosis hsa04666 1.03E-07 37 15
29 GABAergic synapse hsa04727 2.43E-07 36 14
30 Neurotrophin signaling pathway hsa04722 2.73E-07 46 17
31 Endometrial cancer hsa05213 3.52E-07 23 15
32 MAPK signaling pathway hsa04010 3.65E-07 87 17
33 Nicotine addiction hsa05033 7.39E-07 21 11
34 Glutamatergic synapse hsa04724 1.40E-06 46 16
35 HIF-1 signaling pathway hsa04066 1.97E-06 41 14
36 Small cell lung cancer hsa05222 2.21E-06 32 13
37 Retrograde endocannabinoid signaling hsa04723 2.23E-06 44 16
38 Endocytosis hsa04144 4.98E-07 66 16
39 Colorectal cancer hsa05210 5.62E-06 26 13
40 Transcriptional misregulation in cancer hsa05202 8.33E-06 67 17
41 Long-term depression hsa04730 9.52E-06 30 12
42 HTLV-I infection hsa05166 1.01E-05 86 18
43 RNA transport hsa03013 1.03E-05 53 13
44 Gap junction hsa04540 1.32E-05 36 16
45 Serotonergic synapse hsa04726 1.86E-05 41 14
46 Shigellosis hsa05131 1.87E-06 25 13
47 Cholinergic synapse hsa04725 4.80E-05 44 15
48 Progesterone-mediated oocyte maturation hsa04914 8.31E-06 31 15
49 B cell receptor signaling pathway hsa04662 9.67E-05 28 14
50 mRNA surveillance pathway hsa03015 1.58E-04 32 13
51 Melanogenesis hsa04916 0.000226175 35 14
52 Adherens junction hsa04520 0.000287131 34 13
53 p53 signaling pathway hsa04115 0.000626589 25 14
54 Tight junction hsa04530 0.000626589 45 17
55 Chemokine signaling pathway hsa04062 0.000735728 59 17
56 Gastric acid secretion hsa04971 0.000843576 27 13
57 Thyroid cancer hsa05216 0.001230756 12 8
58 Aldosterone-regulated sodium reabsorption hsa04960 0.001230756 15 10
59 Protein processing in endoplasmic reticulum hsa04141 0.001717442 58 15
60 Fc epsilon RI signaling pathway hsa04664 0.001997301 25 14
61 Amyotrophic lateral sclerosis hsa05014 0.002244187 19 12
62 Hedgehog signaling pathway hsa04340 0.003327063 18 10
(continued on next page)
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miRNA reverse transcription, pre-ampliﬁcation and expression
analysis using TaqMan real-time PCR
Total RNA including miRNA fraction was reversely tran-
scribed to cDNA using Megaplex stem-loop RT primer
(Thermo Fisher Scientific, Waltham, MA, USA) for Human
Pool A and B in combination with the TaqMan MicroRNA
Reverse Transcription Kit (Thermo Fisher Scientific, Wal-
tham, MA, USA). This allowed simultaneous cDNA synthesis
of 377 unique miRNAs for Pool A and B each. Except for
biopsy materials, a pre-amplification protocol was performed
for all low content samples to increase the detection rate.
The entire procedure for quantification using TaqMan
OpenArray [25] and TaqMan LDA [28] is described else-
where. miRNAs which were not detectable or above cycle
threshold 28 (OpenArrays) resp. 32 (LDA) were considered
to be absent in the sample.
miRNA labeling and expression analysis using Febit Geniom
Biochip
The expression analysis of all 906 miRNA and miRNA*
sequences as annotated in Sanger miRBase version 14.0 was
performed with the Geniom Real Time Analyzer (Febit,
Heidelberg) and the Geniom biochip MPEA hsapiens V14.
Sample labeling with biotin was carried out by using the
ULS labeling Kit from Kreatech (Amsterdam, The Nether-
lands). All essential steps such as hybridization, washing, as
well as signal amplification and measurement, were done auto-
matically by Geniom Real Time Analyzer. The resulting detec-
tion images were evaluated using the Geniom Wizard Software
for background correction and normalization of generated
data. miRNA expression analyses were carried out using the
normalized and background-subtracted intensity values.
Bioinformatic algorithms and miRNA target identiﬁcation
miRNAs not detectable in all samples of corresponding
biological material were regarded as absent for this material
and disease. All following bioinformatics analyses by pathway
prediction tools were based on the list of these candidates.
Venn diagrams of intersecting sets of miRNAs between differ-
ent tissues and platforms are generated using Venny v2.0
(http://bioinfogp.cnnb.csic.es/tools/venny/index.html). miEAA
(http://www.ccb.uni saarland.de/mieaa_tool) and DIANA
miRPath v.2.0 [31] were used for miRNA target prediction
and pathway analysis. All given lists of miRNAs are translated
and annotated according to miRBase v14 nomenclature.
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Table 6 (continued)
KEGG pathway name KEGG pathway ID P value No. of genes No. of miRNAs
63 African trypanosomiasis hsa05143 0.003397353 13 8
64 RNA degradation hsa03018 0.003476498 25 12
65 Cell cycle hsa04110 0.004653399 44 15
66 Hepatitis C hsa05160 0.005851881 42 15
67 Bacterial invasion of epithelial cells hsa05100 0.006348145 25 13
68 Vascular smooth muscle contraction hsa04270 0.007925320 40 17
69 Dilated cardiomyopathy hsa05414 0.008011601 30 13
70 Circadian rhythm hsa04710 0.008140682 13 10
71 Tuberculosis hsa05152 0.011988530 54 16
72 Type II diabetes mellitus hsa04930 0.012298220 17 10
73 VEGF signaling pathway hsa04370 0.012587870 22 12
74 Adipocytokine signaling pathway hsa04920 0.013372720 23 12
75 Steroid biosynthesis hsa00100 0.017532930 7 6
76 Amoebiasis hsa05146 0.021327710 35 14
77 Salivary secretion hsa04970 0.021801720 28 14
78 Hypertrophic cardiomyopathy hsa05410 0.026359440 27 10
79 Homologous recombination hsa03440 0.029491120 10 7
80 Fanconi anemia pathway hsa03460 0.030397850 18 11
81 Chagas disease (American trypanosomiasis) hsa05142 0.039795790 33 12
82 D-glutamine and D-glutamate metabolism hsa00471 0.040418440 2 4
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Table 7 Pathways generated for the 24 commonly-absent miRNAs using DIANA microT
KEGG pathway name KEGG pathway ID P value No. of genes No. of miRNAs
01 TGF-beta signaling pathway hsa04350 9.96E-35 43 14
02 Chronic myeloid leukemia hsa05220 4.60E-28 40 13
03 ErbB signaling pathway hsa04012 2.74E-18 42 13
04 Prostate cancer hsa05215 7.11E-13 37 14
05 Pathways in cancer hsa05200 1.36E-12 116 16
06 Wnt signaling pathway hsa04310 2.79E-11 60 14
07 Focal adhesion hsa04510 2.79E-11 71 15
08 Axon guidance hsa04360 3.33E-11 54 13
09 PI3 K-Akt signaling pathway hsa04151 3.33E-11 108 17
10 Pancreatic cancer hsa05212 3.65E-11 32 13
11 Acute myeloid leukemia hsa05221 4.43E-11 25 14
12 Melanoma hsa05218 7.58E-12 30 13
13 Non-small cell lung cancer hsa05223 7.92E-11 25 12
14 Renal cell carcinoma hsa05211 1.49E-10 32 16
15 Glioma hsa05214 1.85E-10 32 13
16 Ubiquitin mediated proteolysis hsa04120 2.01E-10 52 15
17 Fc gamma R-mediated phagocytosis hsa04666 1.35E-09 37 14
18 Prion diseases hsa05020 3.26E-09 11 11
19 Long-term potentiation hsa04720 1.83E-08 28 10
20 Dopaminergic synapse hsa04728 2.93E-09 47 14
21 Dorso-ventral axis formation hsa04320 4.36E-08 12 11
22 Small cell lung cancer hsa05222 5.82E-08 32 12
23 Bladder cancer hsa05219 1.14E-07 19 9
24 T cell receptor signaling pathway hsa04660 1.48E-07 39 14
25 Hepatitis B hsa05161 1.84E-10 54 16
26 Insulin signaling pathway hsa04910 2.30E-07 47 15
27 Transcriptional misregulation in cancer hsa05202 2.94E-07 65 16
28 Regulation of actin cytoskeleton hsa04810 5.00E-07 71 15
29 HIF-1 signaling pathway hsa04066 1.44E-06 39 13
30 mTOR signaling pathway hsa04150 2.13E-06 25 11
31 Colorectal cancer hsa05210 2.70E-06 25 12
32 Neurotrophin signaling pathway hsa04722 4.60E-06 42 16
33 Endometrial cancer hsa05213 6.98E-06 21 14
34 Nicotine addiction hsa05033 9.97E-06 19 10
35 Glutamatergic synapse hsa04724 1.35E-05 42 15
36 HTLV-I infection hsa05166 1.57E-05 80 17
37 GABAergic synapse hsa04727 2.31E-05 32 13
38 B cell receptor signaling pathway hsa04662 4.03E-05 27 13
39 Adherens junction hsa04520 4.55E-05 33 12
40 MAPK signaling pathway hsa04010 5.50E-05 78 16
41 Endocytosis hsa04144 7.71E-05 60 15
42 Shigellosis hsa05131 9.06E-05 23 12
43 Serotonergic synapse hsa04726 0.000134263 38 13
44 GnRH signaling pathway hsa04912 0.000209828 30 15
45 Thyroid cancer hsa05216 0.000213265 12 7
46 Aldosterone-regulated sodium reabsorption hsa04960 0.000213265 15 9
47 p53 signaling pathway hsa04115 0.000297667 24 13
48 mRNA surveillance pathway hsa03015 0.000388800 30 12
49 Cholinergic synapse hsa04725 0.000411066 40 14
50 Progesterone-mediated oocyte maturation hsa04914 0.000806986 28 14
51 Chemokine signaling pathway hsa04062 0.000911188 55 16
52 Retrograde endocannabinoid signaling hsa04723 0.001088369 38 15
53 Cell cycle hsa04110 0.001246094 42 14
54 Tight junction hsa04530 0.001246662 42 16
55 Gap junction hsa04540 0.001678051 31 15
56 VEGF signaling pathway hsa04370 0.001810046 22 11
57 Amyotrophic lateral sclerosis (ALS) hsa05014 0.001813055 18 11
58 Bacterial invasion of epithelial cells hsa05100 0.002374269 24 12
59 Melanogenesis hsa04916 0.002639431 32 13
60 Hedgehog signaling pathway hsa04340 0.003261835 17 9
61 Long-term depression hsa04730 0.004371048 26 11
62 Fc epsilon RI signaling pathway hsa04664 0.004700800 23 13
63 RNA degradation hsa03018 0.007308968 23 11
(continued on next page)
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